Singapore markets open in 7 hours 15 minutes
Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,013.44 -8.77 (-0.17%) Dow
37,735.47 -17.84 (-0.05%) Nasdaq
15,632.97 -50.41 (-0.32%) Bitcoin USD
63,229.52 +2,506.16 (+4.13%) CMC Crypto 200
885.54 0.00 (0.00%)
BioMarin Pharmaceutical Inc. (0HNC.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:27PM BST
| Previous close | 90.78 |
| Open | 90.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 89.60 - 91.15 |
| 52-week range | 76.29 - 99.65 |
| Volume | |
| Avg. volume | 5,967 |
| Market cap | 164.895M |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 4.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
© 2024 Yahoo. All rights reserved.